Fuzionaire Diagnostics Revenue and Competitors

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a radiopharmaceutical company. Our radiolableing platform unlocks the power of PET to help detect and treat any disease. The primary barriers to better imaging are the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx’s mission is to radically improve the scope, safety, use, and cost of PET imaging. Our patented HetSiFA™ compositions, which are synthesized using our alkali metal catalysts, can bioconjugate to disease-targeting ligands at record-breaking speed. For the first time, it is possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new way to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision. The platform also has the potential to become a unique tool for drugmakers, providing critical in vivopharmacological data earlier in the drug discovery process. Fuzionaire Dx was co-founded by a team including CEO Nick Slavin, Chief Science Officer Anton Toutov, PhD, and Nova Spivack, and is advised by leading researchers in nuclear medicine and drug discovery.